56 percent of sufferers getting ANA598 plus SOC achieved undetectable levels of virus at week 4.

Anadys expects to initiate dosing in this cohort in January 2010. Related StoriesOncolytic viral therapy accepted in the U.S. For use against late-stage melanomaUC Irvine Wellness researchers develop one-step check to detect HCV infectionsMedStar Washington Hospital Center's Ebola Response Team recognized with 2015 Patient Protection Award’We are very pleased with the 4-week antiviral response and safety for this first dose cohort,’ said Steve Worland, Ph.D., President and CEO.The study, that was released in the Feb. 28, 2008 problem of the American Journal of Physiology – Regulatory, Comparative and Integrative Physiology, indicates that muscles pain and fatigue aren’t independent conditions and could talk about a common pathway that’s disrupted in chronic muscles pain conditions. The group plans to keep their research and investigate whether discomfort enhances fatigue even more in females than men. Our long-term objective is to create better remedies for chronic musculoskeletal discomfort, Sluka said.